Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

MLA

Sapna P. Patel, et al. “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.” New England Journal of Medicine, vol. 388, Mar. 2023, pp. 813–23. EBSCOhost, https://doi.org/10.1056/nejmoa2211437.

APA

Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, … Antoni Ribas. (2023). Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. New England Journal of Medicine, 388, 813–823. https://doi.org/10.1056/nejmoa2211437

Chicago

Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, et al. 2023. “Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.” New England Journal of Medicine 388 (March): 813–23. doi:10.1056/nejmoa2211437.